Advocacy
Neuroendocrine Cancer UK: PERT UPDATE 30th May 2024
As you may be aware, over the last few months, we at Neuroendocrine Cancer UK, have been working with charity partners to address the urgent need to resolve the persistent shortage of PERT (Pancreatic Enzyme Replacement Therapy) medications: Creon®, Nutrizym® 22 and Pancrex V®
You may have seen, read or heard, media reports in local or national media about drug shortages including PERT.
We have been in discussion with charity colleagues, the Department of Health & Social Care (DHSC), the National Medicines Supply Team and Creon’s UK Supplier, Viatris, about the problems people are facing in accessing this essential medication. Together, with charity colleagues, we have been pushing for prioritisation to address these shortages: calling for a proactive, long-term, plan that can ensure a sustainable and equitable supply for those that rely on PERT. We would like to thank those of you who have taken the time to complete our PERT survey – the responses, we have so far received, reflect the concerns we have raised about the impact these shortages are having on people with neuroendocrine cancer – and support the demand for a sustainable resolution to current issues.
We know how important PERT is for controlling symptoms, maintaining people’s quality of life and safeguarding their ability to undergo anti-cancer therapies.
If you or a loved one are having difficulties with PERT, please get in touch if you need support. Our helpline team are here to help: 0800 434 6476 – available Tues-Thurs 10am-4pm or use our Contact Us form and we can arrange to call you.
To read this article in full, please CLICK HERE
New Position Statement with updated patient information is due out at the end of June. We will share this on www.neuroendocrinecancer.org.uk once available.
11
www.neuroendocrinecancer.org.uk
Made with FlippingBook interactive PDF creator